visceral adipose tissue contribute to the propagation of insulin resistance to diabetes mellitus. We tested the hypothesis that new-onset post-transplant diabetes mellitus (PTDM) is associated with measurable changes in Treg subsets following allogeneic hematopoietic stem cell transplantation (HCT).
Tregs to CLA + Tregs (odds ratio, 18.1; P=0.020). PTDM is associated with altered immune regulation post-HCT and could represent a target to modulate alloreactivity.
Introduction
Post-transplant diabetes mellitus (PTDM) occurs in 10-30% of patients undergoing allogeneic hematopoietic cell transplantation (HCT) [1] [2] [3] . Insulin resistance is a prominent characteristic of the metabolic syndrome. This proinflammatory disorder is highly prevalent in survivors of HCT and is associated with increased risk for cardiovascular mortality 4, 5 . Regulatory T cells (Tregs) are an immunosuppressive subset of CD4 + T cells that have been implicated in the prevention of both autoimmune disorders like Type I diabetes mellitus and the inhibition of alloimmune responses including graft-versus-host disease (GVHD) [6] [7] [8] . Recent data suggest that immune dysregulation and impaired accumulation of Tregs in visceral adipose tissue are associated with the development of insulin resistance in animal models 9, 10 . Therefore, we tested the hypothesis that patients with PTDM have altered frequencies of Tregs early after HCT.
Methods

Patients aged
≥ 18 years undergoing myeloablative or reduced intensity conditioning followed by related or unrelated donor (URD) transplant were eligible for two independent Vanderbilt University IRB approved trials examining either PTDM or tissue-specific Tregs. Thirty-six HCT recipients with hematological malignancies but without preexisting diabetes were enrolled in both studies concurrently and were followed for 100 days after HCT for PTDM, Groups were compared using χ 2 for categorical variables and Mann-Whitney U test for continuous outcomes. The primary aim was to test for an association between PTDM and Treg subsets using Mann-Whitney U test and logistic regression for univariate and multivariate analysis, respectively. Kaplan-Meier method was used to estimate overall survival (OS) and disease-free survival (DFS) and groups were compared using the log-rank test. Cumulative incidence was used to estimate non-relapse mortality (NRM), defined as any death occurring in the absence of malignancy relapse or progression. P-values were two-tailed and considered significant at P<0.05.
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Results and Discussion
Among 36 HCT-recipients with prospectively collected metabolic and Treg data, 24 (66.7%) patients developed new-onset PTDM during the first 100 days of transplant (median, 24.5 days post-HCT; range, 7-100 days). Table 1a summarizes cohort characteristics. Grade II-IV acute GVHD occurred in 28 In multivariate analysis adjusting for pre-transplant fasting C-peptide, corticosteroids, and URD, patients with PTDM continued to show an altered distribution of Treg subsets (Table 1b) 13 .
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These data confirm that early PTDM is a common complication following HCT and is associated with inferior transplant outcomes. We found a higher than previously reported incidence of PTDM (66.7%), likely due to prospective data collection, strict diagnostic criteria, and early time-frame post-HCT. We also found that the distribution of Tregs with specific tissue-homing properties was markedly altered in patients who developed PTDM with increased α 4 Animal models have shown a relationship between chronic low-grade inflammation, decreased frequency of Tregs in visceral adipose tissue, and the progression of insulin resistance to diabetes mellitus 9,10 . This observation is potentially mediated by leptin, an adipocyte secreted hormone associated with obesity and diabetes which can decrease the proliferation of Tregs and promote an inflammatory Th1 phenotype [14] [15] [16] . In experimental models, adipocyte inflammation and insulin resistance can be reversed by infusion of Tregs 17 . Thus adipocyte physiology is closely linked to cellular immune responses.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Among HCT recipients, we suspect that early PTDM is caused by progressive insulin resistance related to increased metabolic demands from medications, alloimmune responses, and chronic host adipose tissue inflammation. Adipocyte inflammation and macrophage recruitment to these tissues also could serve as a priming mechanism for GVHD and alloreactivity thus perpetuating the progression of insulin resistance. Unexpectedly, we found that patients with PTDM had increased frequencies of circulating α 4 We have previously shown that increased frequencies of CLA + or α 4 β 7 + Tregs were associated with decreased skin or gut acute GVHD events, respectively 12 .
As predicted by the Treg phenotype, PTDM was associated with skin but not gut GVHD (Table 1a) 
